Mr Marco Gerlinger, Consultant Medical Oncologist
Mr Marco Gerlinger
Consultant Medical Oncologist
About Mr Marco Gerlinger
GMC number: 6117372
Year qualified: 2003
Place of primary qualification: Ludwig Maximilian University of Munich
Areas of expertise
- Adenocarcinoma
- Anal cancer
- Biological therapy
- Bowel cancer
- Cancer care
- Cancer genomics
- Chemotherapy
- Clinical trials
- Colon cancer
- Colorectal cancer
- Gastrointestinal cancers
- Genetic testing
- Immunotherapy
- Liver metastases
- Lynch syndrome
- Medical oncology
- Metastases
- Neoadjuvant
- Oesophageal cancer
- Oligometastic disease
- Rectal cancer
- Small bowel cancer
- Stomach (gastric) cancer
- Targeted therapy
Professional memberships
Articles by Mr Marco Gerlinger
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer.
Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy.
Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas.
Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma.
Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.
Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study.